John Houston, Chairperson, CEO and President at Arvinas (NASDAQ ARVN), shared the following post by Hartford Business Journal on LinkedIn, adding the following:
“Thanks for the great write up on the exciting events happening at Arvinas!”
Quoting Hartford Business Journal:
“With a recent $350 million fundraise, New Haven biotech Arvinas says it’s financed through at least 2027 to pursue bringing its cancer-fighting drugs to market.”
Read further.
Source: John Houston/LinkedIn and Hartford Business Journal/LinkedIn